#USA #New York #Levi & Korsinsky #class action lawsuit #Capricor Therapeutics

In a significant development for stakeholders, Levi & Korsinsky, LLP has formally notified investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) about a class action securities lawsuit. This lawsuit specifically targets allegations of securities fraud that occurred between October 9, 2024, and July 10, 2025. The lawsuit aims to recoup losses suffered by investors during this period. According to the complaint, there are serious claims regarding the misrepresentation of essential information concerning Capricor's lead drug candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Notably, the defendants are accused of providing misleadingly optimistic updates about Capricor's prospects, especially regarding the company's ability to secure a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). These claims were made while allegedly obscuring critical safety and efficacy data derived from Capricor's four-year safety findings from its Phase 2 HOPE-2 trial of deramiocel. The turning point came on July 11, 2025, when Capricor publicly announced it received a Complete Response Letter (CRL) from the FDA. This letter highlighted that the BLA did not comply with the statutory requirements for displaying substantial evidence of drug effectiveness. Moreover, it pointed out the need for additional clinical data to be provided. This information caused a notable decline in Capricor's stock price, dropping from $11.40 per share on July 10 to $7.64 the following day. Investors who were adversely affected by these developments and suffered losses during the specified timeframe must act quickly. There is a deadline of September 15, 2025, for submitting requests to have the court designate them as lead plaintiffs in this case. Importantly, even if one does not serve as a lead plaintiff, they can still be eligible for any potential recovery from this lawsuit. Furthermore, participation in the class action comes at no cost to the investor, meaning they may receive compensation without incurring any out-of-pocket expenses. Levi & Korsinsky is well-acknowledged in the legal domain for its relentless pursuit of justice for shareholders. Over two decades, they have successfully obtained hundreds of millions of dollars in compensation for aggrieved investors, gaining recognition as a top-tier securities litigation firm. With more than 70 professionals dedicated to serving their clients, the firm has ranked in ISS Securities Class Action Services' Top 50 Report as one of the leading securities litigation firms for seven consecutive years. For those looking for more information or wishing to seek legal counsel regarding their situation with Capricor Therapeutics, they can reach out to Joseph E. Levi, Esq. via email or telephone. Interested parties should act expeditiously to meet the impending September 15 deadline to ensure their rights are protected. Contact details are as follows: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 Email: email protected] Phone: (212) 363-7500 Fax: (212) 363-7171 [www.zlk.com This case serves as a crucial reminder for investors concerning the importance of transparency and accuracy in corporate communications, especially when it pertains to products as significant as those impacting health and wellbeing. Stakeholders should remain vigilant about potential risks and legal implications concerning their investments.